4.8 Review

Recent advances in clinical practice: a systematic review of isolated colonic Crohn's disease: the third IBD?

期刊

GUT
卷 66, 期 2, 页码 362-381

出版社

BMJ PUBLISHING GROUP
DOI: 10.1136/gutjnl-2016-312673

关键词

-

资金

  1. MSD
  2. Actavis
  3. AbbVie
  4. Dr Falk Pharmaceuticals
  5. Shire

向作者/读者索取更多资源

The genetics of isolated colonic Crohn's disease place it approximately midway between Crohn's disease with small intestinal involvement and UC, making a case for considering it as a separate condition. We have therefore systematically reviewed its epidemiology, pathophysiology and treatment. Key findings include a higher incidence in females (65%) and older average age at presentation than Crohn's disease at other sites, a mucosa-associated microbiota between that found in ileal Crohn's disease and UC, no response to mesalazine, but possibly better response to antitumour necrosis factor than Crohn's disease at other sites. Diagnostic distinction from UC is often difficult and also needs to exclude other conditions including ischaemic colitis, segmental colitis associated with diverticular disease and tuberculosis. Future studies, particularly clinical trials, but also historical cohorts, should assess isolated colonic Crohn's disease separately.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据